Dipeptidyl Peptidase-4 Inhibitor–Associated Risk of Bleeding: An Evaluation of Reported Adverse Events
- 7 February 2017
- journal article
- research article
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 51 (7) , 563-569
Abstract
Background: Dipeptidyl peptidase-4 (DPP-4) inhibitors improve glycemic control, and sitagliptin has been associated with a reduction in cardiovascular events. In vivo data suggest reduced platelet activation, and aggregation may play a role, and therefore, increased bleeding risk is possible. Objective: Comparatively assess bleeding risks associated with DPP-4 inhibitors against standard treatment. Methods: Exploratory analyses of adverse event reports (AERs) from the US Food and Drug Administration Adverse Event Reporting System (FAERS) database (2004-2012 periods) were conducted. DPP-4 inhibitor–related bleeding was assessed with metformin as negative control, and aspirin, clopidogrel, and prasugrel illustrated positive comparators. Reporting odds ratios (RORs) and 95% CIs were calculated as a measure of disproportionality of reporting, and RORs were compared across drugs with the Breslow-Day statistics. Results: From 2004 to 2012, 36 298, 4288, and 1202 AERs were found for sitagliptin, saxagliptin, and linagliptin, respectively, with 863, 102, and 14 bleeding complications. The relative reporting rate was not elevated with any DPP-4 inhibitor (sitagliptin: ROR = 0.71, 95% CI = 0.67-0.76; saxagliptin: ROR = 0.72, 95% CI = 0.59-0.87; linagliptin: ROR = 0.35, 95% CI = 0.20-0.59) or with metformin (ROR = 0.77; 95% CI = 0.75-0.78). Sitagliptin showed relatively higher reporting as compared with linagliptin (P = 0.006) but not with saxagliptin (P = 0.98). As positive references, antiplatelet drugs demonstrated relatively higher reporting compared with metformin (aspirin: ROR = 1.50, 95% CI = 1.48-1.51; clopidogrel: ROR = 2.28, 95% CI = 2.23-2.33; prasugrel: ROR = 5.09, 95% CI = 4.57-5.67). Conclusion: DPP-4 inhibitors were not associated with an undue increase in bleeding AERs in the FAERS database.Keywords
This publication has 23 references indexed in Scilit:
- Safety and Tolerability of Sitagliptin in Type 2 Diabetes: Pooled Analysis of 25 Clinical StudiesDiabetes Therapy, 2013
- Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysisCardiovascular Diabetology, 2013
- Data Mining of the Public Version of the FDA Adverse Event Reporting SystemInternational Journal of Medical Sciences, 2013
- DPP-4 InhibitorsDiabetes Care, 2011
- Sitagliptin reduces albuminuria in patients with type 2 diabetes [Rapid Communication]Endocrine Journal, 2011
- Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetesBMC Endocrine Disorders, 2010
- Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular CausesNew England Journal of Medicine, 2007
- Type 2 diabetes—Therapy with dipeptidyl peptidase IV inhibitorsBiochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 2005
- Perspectives on the Use of Data Mining in PharmacovigilanceDrug Safety, 2005
- A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)The Lancet, 1996